Immunome (NASDAQ:IMNM) Price Target Lowered to $21.00 at Piper Sandler

Immunome (NASDAQ:IMNM) had its price objective trimmed by Piper Sandler from $23.00 to $21.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other research analysts have also weighed in on IMNM. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Immunome in a research report on Friday, October 25th. Stephens began coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $28.83.

Immunome Stock Down 11.0 %

Shares of NASDAQ IMNM traded down $1.23 during mid-day trading on Thursday, hitting $9.91. 3,162,245 shares of the company traded hands, compared to its average volume of 767,025. Immunome has a 1 year low of $6.93 and a 1 year high of $30.96. The stock has a market capitalization of $595.14 million, a price-to-earnings ratio of -1.28 and a beta of 1.82. The business has a 50 day moving average of $13.19 and a two-hundred day moving average of $13.82.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.62 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.36%. As a group, research analysts anticipate that Immunome will post -1.92 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Max Rosett sold 14,380 shares of the company’s stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total transaction of $230,223.80. Following the completion of the sale, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This represents a 23.25 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Several large investors have recently made changes to their positions in IMNM. EntryPoint Capital LLC boosted its stake in Immunome by 21,864.0% during the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares during the period. Quest Partners LLC bought a new stake in Immunome during the 2nd quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Immunome during the 2nd quarter valued at approximately $97,000. Arizona State Retirement System boosted its stake in Immunome by 9.2% during the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Immunome during the 3rd quarter valued at approximately $219,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.